PheVI:09 (Phe6.44) as a Sliding Microswitch in Seven-transmembrane (7TM) G Protein-coupled Receptor Activation*

Background: PheVI:09 (6.44) is highly conserved among 7TM receptors. Results: In the inactive state, PheVI:09 is locked against the backbone of TM-III but slides pass IleIII:16 (3.40) into a tight hydrophobic pocket between TM-III and TM-V during receptor activation. Conclusion: Mutational analysis and computational chemistry shows that PheVI:09 functions as a microswitch. Significance: This work clarifies the molecular mechanism of a crucial microswitch in 7TM receptor activation. In seven-transmembrane (7TM), G protein-coupled receptors, highly conserved residues function as microswitches, which alternate between different conformations and interaction partners in an extended allosteric interface between the transmembrane segments performing the large scale conformational changes upon receptor activation. Computational analysis using x-ray structures of the β2-adrenergic receptor demonstrated that PheVI:09 (6.44), which in the inactive state is locked between the backbone and two hydrophobic residues in transmembrane (TM)-III, upon activation slides ∼2 Å toward TM-V into a tight pocket generated by five hydrophobic residues protruding from TM-III and TM-V. Of these, the residue in position III:16 (3.40) (often an Ile or Val) appears to function as a barrier or gate for the transition between inactive and active conformation. Mutational analysis showed that PheVI:09 is essential for the constitutive and/or agonist-induced signaling of the ghrelin receptor, GPR119, the β2-adrenergic receptor, and the neurokinin-1 receptor. Substitution of the residues constituting the hydrophobic pocket between TM-III and TM-V in the ghrelin receptor in four of five positions impaired receptor signaling. In GPR39, representing the 12% of 7TM receptors lacking an aromatic residue at position VI:09, unchanged agonist-induced signaling was observed upon Ala substitution of LeuVI:09 despite reduced cell surface expression of the mutant receptor. It is concluded that PheVI:09 constitutes an aromatic microswitch that stabilizes the active, outward tilted conformation of TM-VI relative to TM-III by sliding into a tight hydrophobic pocket between TM-III and TM-V and that the hydrophobic residue in position III:16 constitutes a gate for this transition.

[1]  T. Schwartz,et al.  Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism* , 2007, Journal of Biological Chemistry.

[2]  Thomas M Frimurer,et al.  Ligand binding and micro-switches in 7TM receptor structures. , 2009, Trends in pharmacological sciences.

[3]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[4]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[5]  F Guarnieri,et al.  Agonist-induced Conformational Changes at the Cytoplasmic Side of Transmembrane Segment 6 in the β2 Adrenergic Receptor Mapped by Site-selective Fluorescent Labeling* , 2001, The Journal of Biological Chemistry.

[6]  T. Sakmar,et al.  The Effects of Amino Acid Replacements of Glycine 121 on Transmembrane Helix 3 of Rhodopsin* , 1996, The Journal of Biological Chemistry.

[7]  C Giuliani,et al.  The thyrotropin receptor. , 1995, Vitamins and hormones.

[8]  Leonardo Pardo,et al.  An Activation Switch in the Rhodopsin Family of G Protein-coupled Receptors , 2005, Journal of Biological Chemistry.

[9]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[10]  R. Riek,et al.  Mutation of a single TMVI residue, Phe(282), in the beta(2)-adrenergic receptor results in structurally distinct activated receptor conformations. , 2002, Biochemistry.

[11]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[12]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[13]  T. Schwartz,et al.  Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.

[14]  Mark Gerstein,et al.  MolMovDB: analysis and visualization of conformational change and structural flexibility , 2003, Nucleic Acids Res..

[15]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[16]  S. W. Lin,et al.  Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. , 1996, Biochemistry.

[17]  C. Altenbach,et al.  High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation , 2008, Proceedings of the National Academy of Sciences.

[18]  T. Sakmar,et al.  Functional Interaction of Transmembrane Helices 3 and 6 in Rhodopsin , 1996, The Journal of Biological Chemistry.

[19]  M. Birnbaumer,et al.  Mutations of the DRY motif that preserve beta 2-adrenoceptor coupling. , 1998, Receptors & channels.

[20]  Oliver P. Ernst,et al.  Crystal structure of metarhodopsin II , 2011, Nature.

[21]  T. Schwartz,et al.  Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. , 1998, Molecular pharmacology.

[22]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[23]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[24]  S. Wodak,et al.  A Conserved Asn in Transmembrane Helix 7 Is an On/Off Switch in the Activation of the Thyrotropin Receptor* , 2001, The Journal of Biological Chemistry.

[25]  Mark Gerstein,et al.  Normal modes for predicting protein motions: A comprehensive database assessment and associated Web tool , 2005, Protein science : a publication of the Protein Society.

[26]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[27]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[28]  Thomas M Frimurer,et al.  A Conserved Aromatic Lock for the Tryptophan Rotameric Switch in TM-VI of Seven-transmembrane Receptors* , 2009, The Journal of Biological Chemistry.

[29]  T. Schwartz,et al.  The Arginine of the DRY Motif in Transmembrane Segment III Functions as a Balancing Micro-switch in the Activation of the β2-Adrenergic Receptor , 2012, The Journal of Biological Chemistry.

[30]  M. Brann,et al.  Identification of a Ligand-dependent Switch within a Muscarinic Receptor* , 1998, The Journal of Biological Chemistry.

[31]  B. Roques,et al.  Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. , 1998, Molecular pharmacology.

[32]  R. Graham,et al.  Phe(303) in TMVI of the alpha(1B)-adrenergic receptor is a key residue coupling TM helical movements to G-protein activation. , 2002, Biochemistry.

[33]  Thomas M Frimurer,et al.  Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor , 2009, Molecular Pharmacology.

[34]  Viktor Hornak,et al.  Location of Trp265 in metarhodopsin II: implications for the activation mechanism of the visual receptor rhodopsin. , 2006, Journal of molecular biology.